Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 62.2%

Neg 62.2% Neu 0% Pos 0%

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $40 to $20.